Molecular remission after allogeneic or autologou8 transplantation of hematopoietic stem cells for multiple myeloma

Giovanni G. Martinelli; Carolina C. Terragna; Elena E. Zamagni; Sonia S. Ronconi; Patrizia P. Tosi; Roberto Massimco R M Lemoli; Giuseppe G. Bandini; Maria Rosa M R Motta; Nicoletts N. Testoni; Marilina M. Amabile; Emanuela E. Ottaviani; Nicola Nj Vianelli; Antonio A. De Vivo; Alessandro A. Gozzetti; Santé S. Turamichèle M Cavo

Molecular remission after allogeneic or autologou8 transplantation of hematopoietic stem cells for multiple myeloma

Giovanni G. Martinelli, Carolina C. Terragna, Elena E. Zamagni, Sonia S. Ronconi, Patrizia P. Tosi, Roberto Massimco R M Lemoli, Giuseppe G. Bandini, Maria Rosa M R Motta, Nicoletts N. Testoni, Marilina M. Amabile, Emanuela E. Ottaviani, Nicola Nj Vianelli, Antonio A. De Vivo, Alessandro A. Gozzetti, Santé S. Turamichèle M Cavo

Research output: Contribution to journal › Article › peer-review

Abstract

To assess clinical relevance of minimal residual disease (MRD) in patients withj multiple myeloma (MM), 50 patients were monitored in complete clinical remission (CCR) after autologous or allogeneic stem cell transplantation. Stringent molecular monitoring using clonal markers based upon rearranged! immunoglobulin heavy-chain genes was done in 44/50 MM patients in CCR. Molecular! remission (MCR) was defined as 1 consecutive negative PCR results. 12/44 (27%) molecularly monitored patients achieved MCR; 4/12 turned PCR+ and 1 /4 relapsed. Patients achieving MCR had a significantly lower relapse rate (16% vs. 41% ; I p

Original language	English
Journal	Blood
Volume	96
Issue number	11 PART I
Publication status	Published - 2000

ASJC Scopus subject areas

Hematology

Fingerprint Dive into the research topics of 'Molecular remission after allogeneic or autologou8 transplantation of hematopoietic stem cells for multiple myeloma'. Together they form a unique fingerprint.

Cite this

Martinelli, G. G., Terragna, C. C., Zamagni, E. E., Ronconi, S. S., Tosi, P. P., Lemoli, R. M. R. M., Bandini, G. G., Motta, M. R. M. R., Testoni, N. N., Amabile, M. M., Ottaviani, E. E., Vianelli, N. N., De Vivo, A. A., Gozzetti, A. A., & Turamichèle M Cavo, S. S. (2000). Molecular remission after allogeneic or autologou8 transplantation of hematopoietic stem cells for multiple myeloma. Blood, 96(11 PART I).

Molecular remission after allogeneic or autologou8 transplantation of hematopoietic stem cells for multiple myeloma. / Martinelli, Giovanni G.; Terragna, Carolina C.; Zamagni, Elena E.; Ronconi, Sonia S.; Tosi, Patrizia P.; Lemoli, Roberto Massimco R M; Bandini, Giuseppe G.; Motta, Maria Rosa M R; Testoni, Nicoletts N.; Amabile, Marilina M.; Ottaviani, Emanuela E.; Vianelli, Nicola Nj; De Vivo, Antonio A.; Gozzetti, Alessandro A.; Turamichèle M Cavo, Santé S.

In: Blood, Vol. 96, No. 11 PART I, 2000.

Research output: Contribution to journal › Article › peer-review

Martinelli, Giovanni G. ; Terragna, Carolina C. ; Zamagni, Elena E. ; Ronconi, Sonia S. ; Tosi, Patrizia P. ; Lemoli, Roberto Massimco R M ; Bandini, Giuseppe G. ; Motta, Maria Rosa M R ; Testoni, Nicoletts N. ; Amabile, Marilina M. ; Ottaviani, Emanuela E. ; Vianelli, Nicola Nj ; De Vivo, Antonio A. ; Gozzetti, Alessandro A. ; Turamichèle M Cavo, Santé S. / Molecular remission after allogeneic or autologou8 transplantation of hematopoietic stem cells for multiple myeloma. In: Blood. 2000 ; Vol. 96, No. 11 PART I.

@article{2bc62b6db21449dfa083396263627120,

title = "Molecular remission after allogeneic or autologou8 transplantation of hematopoietic stem cells for multiple myeloma",

abstract = "To assess clinical relevance of minimal residual disease (MRD) in patients withj multiple myeloma (MM), 50 patients were monitored in complete clinical remission (CCR) after autologous or allogeneic stem cell transplantation. Stringent molecular monitoring using clonal markers based upon rearranged! immunoglobulin heavy-chain genes was done in 44/50 MM patients in CCR. Molecular! remission (MCR) was defined as 1 consecutive negative PCR results. 12/44 (27%) molecularly monitored patients achieved MCR; 4/12 turned PCR+ and 1 /4 relapsed. Patients achieving MCR had a significantly lower relapse rate (16% vs. 41% ; I p ",

author = "Martinelli, {Giovanni G.} and Terragna, {Carolina C.} and Zamagni, {Elena E.} and Ronconi, {Sonia S.} and Tosi, {Patrizia P.} and Lemoli, {Roberto Massimco R M} and Bandini, {Giuseppe G.} and Motta, {Maria Rosa M R} and Testoni, {Nicoletts N.} and Amabile, {Marilina M.} and Ottaviani, {Emanuela E.} and Vianelli, {Nicola Nj} and {De Vivo}, {Antonio A.} and Gozzetti, {Alessandro A.} and {Turamich{\`e}le M Cavo}, {Sant{\'e} S.}",

year = "2000",

language = "English",

volume = "96",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "11 PART I",

}

TY - JOUR

T1 - Molecular remission after allogeneic or autologou8 transplantation of hematopoietic stem cells for multiple myeloma

AU - Martinelli, Giovanni G.

AU - Terragna, Carolina C.

AU - Zamagni, Elena E.

AU - Ronconi, Sonia S.

AU - Tosi, Patrizia P.

AU - Lemoli, Roberto Massimco R M

AU - Bandini, Giuseppe G.

AU - Motta, Maria Rosa M R

AU - Testoni, Nicoletts N.

AU - Amabile, Marilina M.

AU - Ottaviani, Emanuela E.

AU - Vianelli, Nicola Nj

AU - De Vivo, Antonio A.

AU - Gozzetti, Alessandro A.

AU - Turamichèle M Cavo, Santé S.

PY - 2000

Y1 - 2000

N2 - To assess clinical relevance of minimal residual disease (MRD) in patients withj multiple myeloma (MM), 50 patients were monitored in complete clinical remission (CCR) after autologous or allogeneic stem cell transplantation. Stringent molecular monitoring using clonal markers based upon rearranged! immunoglobulin heavy-chain genes was done in 44/50 MM patients in CCR. Molecular! remission (MCR) was defined as 1 consecutive negative PCR results. 12/44 (27%) molecularly monitored patients achieved MCR; 4/12 turned PCR+ and 1 /4 relapsed. Patients achieving MCR had a significantly lower relapse rate (16% vs. 41% ; I p

AB - To assess clinical relevance of minimal residual disease (MRD) in patients withj multiple myeloma (MM), 50 patients were monitored in complete clinical remission (CCR) after autologous or allogeneic stem cell transplantation. Stringent molecular monitoring using clonal markers based upon rearranged! immunoglobulin heavy-chain genes was done in 44/50 MM patients in CCR. Molecular! remission (MCR) was defined as 1 consecutive negative PCR results. 12/44 (27%) molecularly monitored patients achieved MCR; 4/12 turned PCR+ and 1 /4 relapsed. Patients achieving MCR had a significantly lower relapse rate (16% vs. 41% ; I p

UR - http://www.scopus.com/inward/record.url?scp=33748651017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748651017&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748651017

VL - 96

JO - Blood

JF - Blood

SN - 0006-4971

IS - 11 PART I

ER -